- Home
- AKAN vs JAGX Comparison
AKAN vs JAGX Comparison
Compare AKAN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- JAGX
- Stock Information
- Founded
- AKAN 2021
- JAGX 2013
- Country
- AKAN Canada
- JAGX United States
- Employees
- AKAN 2
- JAGX N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- AKAN Health Care
- JAGX Health Care
- Exchange
- AKAN Nasdaq
- JAGX Nasdaq
- Market Cap
- AKAN 2.9M
- JAGX 3.4M
- IPO Year
- AKAN 2022
- JAGX N/A
- Fundamental
- Price
- AKAN $1.27
- JAGX $2.24
- Analyst Decision
- AKAN
- JAGX Strong Buy
- Analyst Count
- AKAN 0
- JAGX 1
- Target Price
- AKAN N/A
- JAGX $60.00
- AVG Volume (30 Days)
- AKAN 45.8K
- JAGX 99.7K
- Earning Date
- AKAN 08-05-2025
- JAGX 08-12-2025
- Dividend Yield
- AKAN N/A
- JAGX N/A
- EPS Growth
- AKAN N/A
- JAGX N/A
- EPS
- AKAN N/A
- JAGX N/A
- Revenue
- AKAN $836,664.00
- JAGX $11,552,000.00
- Revenue This Year
- AKAN N/A
- JAGX $22.41
- Revenue Next Year
- AKAN N/A
- JAGX $30.00
- P/E Ratio
- AKAN N/A
- JAGX N/A
- Revenue Growth
- AKAN 97.47
- JAGX 13.93
- 52 Week Low
- AKAN $0.93
- JAGX $2.19
- 52 Week High
- AKAN $4.10
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- AKAN 47.37
- JAGX 29.03
- Support Level
- AKAN $1.12
- JAGX $2.32
- Resistance Level
- AKAN $1.35
- JAGX $2.79
- Average True Range (ATR)
- AKAN 0.10
- JAGX 0.14
- MACD
- AKAN -0.01
- JAGX 0.08
- Stochastic Oscillator
- AKAN 40.54
- JAGX 8.33
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.